Archives: Agenda

• Assessing site capabilities, patient populations, and operational resources to ensure realistic trial execution.
• Using data-driven approaches and analytics to predict enrollment timelines and potential bottlenecks.
• Identifying and mitigating risks early to improve study efficiency and reduce delays.
• Incorporating patient insights and stakeholder feedback to design feasible, patient-friendly protocols.

• The Good Friday Agreement: How politics helped deliver the health dividend of peace on the island of Ireland
• The All-Island Cancer Research Institute (AICRI) a united approach to cancer research and innovation
• How a collaborative cancer research and innovation agenda is empowering the island of Ireland to punch above its weight
• How a unified national collaborative clinical trials ecosystem, underpinned by the formation of the National Clinical Trials Oversight Group, is raising the bar and delivering innovative treatments for Irish patients
• Empowering the Economic Dividend of Health: Providing the innovation and research excellence milieu for industry and academic clinical trials and Real-World Evidence studies to flourish North, South, East and West: maximising the opportunities for cross-border success

• Who is LifeArc?
• The Rare Disease Challenge
• LifeArc’s Approach to Accelerating Clinical Research
• Translational Centres for Rare Disease
• Rare Disease Clinical Trials Programme

• Leveraging AI tools to optimize patient recruitment, site selection, and trial feasibility.
• Using AI for real-time data monitoring, quality checks, and endpoint analysis.
• Integrating AI solutions seamlessly into trial workflows to support operational efficiency.
• Ensuring regulatory compliance, validation, and transparency when deploying AI in active studies.

Harnessing the convergence of high-fidelity data with advanced AI is now essential for de-risking clinical trials and accelerating therapies to patients. What if the distance between a draft protocol and a validated study execution plan was reduced to a single, unified simulation?

Join Medidata’s Eleanor McLaurin for a deep dive into the future of holistic trial design and planning. Learn how advanced modelling and simulation capabilities within a central workspace can revolutionise trial operations. This session will illustrate Medidata’s strategy for optimizing protocol design, predicting trial outcomes, and achieving greater clinical and operational success in the next generation of drug development.

• The hidden assumptions embedded in RFP design that narrow vendor capabilities​
• How RFP structure shapes partnership dynamics and long-term outcomes​
• Rethinking RFP strategy to access broader CRO expertise and innovation​